Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

University of British Columbia

ClinicalTrials.gov lists University of British Columbia as lead sponsor of 1,332 trials. It has 214 active development programs and 190 approved assets.

CA Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

105 0 1996 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 59 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 70 in 2026 and about 74 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 3 trials are registered to start in 2027 or later.

Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers University of British Columbia: 1,332 lead-sponsored trials and 1 legal-entity registration.

Get the University of British Columbia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (597)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Pain 79
Diabetes Mellitus 75
Spinal Cord Injuries 52
Diabetes Mellitus, Type 2 37
Stroke 36

Trials by start year as sponsor or collaborator (30)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 59
2025 76
2024 83
2023 83
2022 80
2021 86
2020 62
2019 72
2018 95
2017 78

Prediction, not a registry value: median of 36 months from start to primary completion across 126 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 789 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (214)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Cannabidiol Bipolar Disorder Phase 3 1
Gabapentin Pain Phase 3 2
Olmesartan COVID-19 Phase 3 1
Cefazolin and Moxifloxacin Emergencies Phase 3 1
Cefazolin and Moxifloxacin Cellulitis Phase 3 1

Approved assets (190)

Shown in this order: max phase first.

Approved assets
Drug Trials
Exercise 19
PROPOFOL 7
BOTULINUM TOXIN TYPE-A 6
DEXMEDETOMIDINE 6
SALBUTAMOL 4

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
45% hit target (n=318) 37% on time (n=309)

Journals published in (1,341)

Shown in this order: most published in first.

Journals published in
Journal Publications
The New England journal of medicine 61
BMJ open 54
The Cochrane database of systematic reviews 53
PloS one 51
Archives of physical medicine and rehabilitation 47

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
936 122 2025-11-18

Financing and grant events (51)

Shown in this order: most recent first.

Financing and grant events
Date Round type Amount (USD) Source
2025-08-22 NIH grant 572,546 Reporter
2025-02-13 NIH grant 396,360 Reporter
2024-12-12 NIH grant 472,791 Reporter
2024-09-24 NIH grant 572,368 Reporter
2024-09-16 NIH grant 295,600 Reporter

Organization relationships (171)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
University of Calgary Co sponsors trial with 19
Université Laval Co sponsors trial with 13
McGill University Health Centre Co sponsors trial with 11
Vancouver Coastal Health Co sponsors trial with 10
University Health Network, Toronto Co sponsors trial with 9

Latest dated events (2,588)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (1,007)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCA2 Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)
ABCC6 Trial sponsor Named in trial inclusion criteria
ACE Trial collaborator Named in trial inclusion criteria
ACE Trial sponsor Named in trial inclusion criteria
ACO2 Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)

Biomarkers this organization publishes on (2,005)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
INS 97
IL6 96
CRP 95
TNF 79
CD4 78

On Scientist.com

University of British Columbia is listed as a research supplier in the Scientist.com network.

University of British Columbia performs medical research.

Website
peptidisc.com

Source: Scientist.com supplier network

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.

Work with University of British Columbia on Scientist.com

For prices, more details, or to contact University of British Columbia, visit Scientist.com.

Sign in to Scientist.com to open this supplier in your organization's marketplace.